Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders
Brain Communications · 2024-10-30 · 6 (6)
DOI: 10.1093/braincomms/fcae414 ↗At a glance
Journal article in Brain Communications, published online on 2024-11-19. Written by Bárbara Fernandes Gomes and 9 co-authors. Institution: Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180…. Cited 7 times so far (Crossref); 30 references. The full text is freely available (open access, CC BY 4.0). Funded by: NIA NIH HHS, Horizon 2020, Marie Skłodowska-Curie.
Abstract (original language)
Disease-specific fluid biomarkers are in demand for parkinsonian syndromes (PS). Corticotropin-releasing hormone (CRH) was proposed as a biomarker for Lewy body disease. As such, this project aimed to confirm CRH as a potential biomarker for different PS. CRH and misfolded α-synuclein (αSyn) were measured in CSF. The primary cohort included Lewy body disease patients (i.e. Parkinson’s disease or dementia with Lewy bodies, n = 77), atypical PS (n = 37) and non-parkinsonian neurodegenerative diseases (n = 164), as well as controls (n = 354). A replication cohort included Lewy body disease (n = 27), atypical PS (n = 58) and controls (n = 58). CRH was downregulated in αSyn positive Lewy body disease, αSyn positive controls and in all atypical PS compared with αSyn negative controls (P = 3.3e−05, P = 3.1e−10, P = 2.9e−03). CRH was also decreased in αSyn positive Lewy body disease compared with αSyn negative non-PS (P = 2e−03) and correlated with cognitive impairment and inflammation in αSyn positive Lewy body disease. We show that CRH is a promising biomarker for Lewy body disease and atypical PS and its association with inflammation and cognitive decline. Reductions in CRH in Lewy body disease and other PS suggest this decrease may relate to dopaminergic degeneration instead of αSyn pathology.
Subjects
Author keywords
Authors and institutions
- Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at the University of Gothenburg, 43180 Mölndal, Sweden.
- Department of Clinical Sciences Malmö, Clinical Memory Research Unit, Lund University, 20213 Malmö, Sweden.
- Banner Alzheimer's Institute and University of Arizona, Phoenix, AZ 85006, USA.
- Banner Sun Health Research Institute, Sun City, AZ 85351, USA.
- Memory Clinic, Skåne University Hospital, 20502 Malmö, Sweden.
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, 43139 Mölndal, Sweden.
ORCID profiles: Bárbara Fernandes Gomes, Atul Kumar, Sara Hall, Ruben Smith, Henrik Zetterberg, Niklas Mattsson-Carlgren, Oskar Hansson
Funding
- NIA NIH HHS
- Horizon 2020
- Marie Skłodowska-Curie
- European Research Council
- Alzheimer's Association
- GHR Foundation
- Swedish Research Council
- ERA PerMed
Cite
APA
Fernandes Gomes, B., Kumar, A., Ashton, N. J., Hall, S., Stomrud, E., Smith, R., Zetterberg, H., Blennow, K., Mattsson-Carlgren, N., & Hansson, O. (2024). Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders. Brain Communications, 6(6). https://doi.org/10.1093/braincomms/fcae414
Vancouver
Fernandes Gomes B, Kumar A, Ashton NJ, Hall S, Stomrud E, Smith R, et al. Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders. Brain Communications. 2024;6(6). doi:10.1093/braincomms/fcae414
BibTeX
@article{FernandesGomes2024,
author = {Fernandes Gomes, Bárbara and Kumar, Atul and Ashton, Nicholas J and Hall, Sara and Stomrud, Erik and Smith, Ruben and Zetterberg, Henrik and Blennow, Kaj and Mattsson-Carlgren, Niklas and Hansson, Oskar},
title = {Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders},
journal = {Brain Communications},
year = {2024},
volume = {6},
number = {6},
doi = {10.1093/braincomms/fcae414}
}
EUVIMED